NASDAQ:LUNG Pulmonx (LUNG) Stock Price, News & Analysis $6.49 +0.19 (+3.02%) (As of 07/5/2024 ET) Add Compare Share Share Today's Range$6.20▼$6.5150-Day Range$5.77▼$9.8252-Week Range$5.67▼$14.84Volume130,759 shsAverage Volume376,022 shsMarket Capitalization$251.92 millionP/E RatioN/ADividend YieldN/APrice Target$15.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Pulmonx alerts: Email Address Pulmonx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside142.1% Upside$15.71 Price TargetShort InterestHealthy3.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$94,585 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector550th out of 879 stocksSurgical & Medical Instruments Industry66th out of 95 stocks 3.4 Analyst's Opinion Consensus RatingPulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePulmonx has only been the subject of 2 research reports in the past 90 days.Read more about Pulmonx's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.99% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmonx has recently decreased by 11.39%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUNG. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for LUNG on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $94,585.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pulmonx's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pulmonx are expected to remain at ($1.63) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pulmonx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About Pulmonx Stock (NASDAQ:LUNG)Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Read More LUNG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUNG Stock News HeadlinesJune 6, 2024 | insidertrades.comPulmonx Co. (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 4,297 SharesJune 6, 2024 | insidertrades.comInsider Selling: Pulmonx Co. (NASDAQ:LUNG) General Counsel Sells 5,475 Shares of StockJuly 6, 2024 | Paradigm Press (Ad)Biden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.June 29, 2024 | americanbankingnews.comBrokerages Set Pulmonx Co. (NASDAQ:LUNG) Target Price at $15.71May 6, 2024 | globenewswire.comPulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 4, 2024 | finance.yahoo.comEarnings Update: Pulmonx Corporation (NASDAQ:LUNG) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsMay 3, 2024 | finance.yahoo.comPulmonx First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | finance.yahoo.comPulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call TranscriptJuly 6, 2024 | Paradigm Press (Ad)Biden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.May 2, 2024 | markets.businessinsider.comAnalyst Recommendation Report Summary: Insights and Strategic Investment PerspectivesMay 2, 2024 | marketwatch.comPulmonx Surge After Strong 1Q PerformanceMay 2, 2024 | finance.yahoo.comQ1 2024 Pulmonx Corp Earnings CallMay 2, 2024 | finance.yahoo.comPulmonx Corp (LUNG) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ...May 1, 2024 | investorplace.comLUNG Stock Earnings: Pulmonx Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | finance.yahoo.comPulmonx Corp (LUNG) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Continued LossesMay 1, 2024 | globenewswire.comPulmonx Reports First Quarter 2024 Financial ResultsApril 25, 2024 | finance.yahoo.comPulmonx Corporation (LUNG) Stock Price, News, Quote & History - Yahoo FinanceApril 10, 2024 | globenewswire.comPulmonx to Report First Quarter 2024 Financial Results on May 1, 2024See More Headlines Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/06/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LUNG CUSIPN/A CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees279Year FoundedN/APrice Target and Rating Average Stock Price Target$15.71 High Stock Price Target$18.00 Low Stock Price Target$12.00 Potential Upside/Downside+142.1%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,840,000.00 Net Margins-80.46% Pretax Margin-79.59% Return on Equity-48.09% Return on Assets-32.61% Debt Debt-to-Equity Ratio0.29 Current Ratio6.95 Quick Ratio6.14 Sales & Book Value Annual Sales$72.99 million Price / Sales3.45 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book2.10Miscellaneous Outstanding Shares38,816,000Free Float36,603,000Market Cap$251.92 million OptionableOptionable Beta0.62 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. David A. Lehman (Age 63)General Counsel & Secretary Comp: $651.39kMr. Geoffrey Beran Rose (Age 50)Chief Commercial Officer Comp: $632.29kMr. Steven S. Williamson (Age 51)CEO, President & Director Mr. Mehul Joshi (Age 63)Chief Financial Officer Mr. Sri RadhakrishnanChief Technical OfficerMs. Marcee M. Maroney (Age 54)Vice President of Marketing Sarah HuberVice President of Sales (U.S.)Ms. Lisa Paul (Age 60)Chief People Officer Mr. Jérôme ErathSenior VP & GM of Europe Middle-East & AfricaMr. John B. McKune (Age 48)VP & Corporate Controller More ExecutivesKey CompetitorsAtrionNASDAQ:ATRIOrthoPediatricsNASDAQ:KIDSEmbectaNASDAQ:EMBCPerspective TherapeuticsNYSE:CATXPulse BiosciencesNASDAQ:PLSEView All CompetitorsInsiders & InstitutionsGeoffrey Beran RoseSold 1,184 sharesTotal: $7,293.44 ($6.16/share)Geoffrey Beran RoseSold 4,297 sharesTotal: $29,950.09 ($6.97/share)David Aaron LehmanSold 5,475 sharesTotal: $38,160.75 ($6.97/share)Geoffrey Beran RoseSold 1,184 sharesTotal: $10,312.64 ($8.71/share)Jacobs Levy Equity Management Inc.Sold 167,457 shares on 5/16/2024Ownership: 0.508%View All Insider TransactionsView All Institutional Transactions LUNG Stock Analysis - Frequently Asked Questions How have LUNG shares performed this year? Pulmonx's stock was trading at $12.75 on January 1st, 2024. Since then, LUNG stock has decreased by 49.1% and is now trading at $6.49. View the best growth stocks for 2024 here. How were Pulmonx's earnings last quarter? Pulmonx Co. (NASDAQ:LUNG) released its quarterly earnings results on Wednesday, May, 1st. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The firm earned $18.85 million during the quarter, compared to analyst estimates of $17.54 million. Pulmonx had a negative net margin of 80.46% and a negative trailing twelve-month return on equity of 48.09%. When did Pulmonx IPO? Pulmonx (LUNG) raised $100 million in an IPO on Thursday, October 1st 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LUNG) was last updated on 7/6/2024 by MarketBeat.com Staff From Our Partners50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LUNG Stock Alerts